Q-omics provides the consensus-scored TNFRSF13B profile across patient tissues and cancer cell-line models. TNFRSF13B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TNFRSF13B is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, TNFRSF13B RNA expression shows 17,474 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where TNFRSF13B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF13B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF13B survival associations across molecular data types. TNFRSF13B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF13B RNA expression–survival associations across cancer types. High TNFRSF13B expression shows favorable associations in HNSC, SKCM, LUAD, BRCA, CESC and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TNFRSF13B RNA expression.
This table summarizes TNFRSF13B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TNFRSF13B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF13B shows lower tumor expression in COAD, BLCA, READ and UCEC and higher tumor expression in KIRC and LUAD. The COAD box plot shows higher TNFRSF13B RNA expression in normal versus tumor tissue (log2 FC = −1.920, t-test p < 0.001).
This table shows molecular features associated with TNFRSF13B in patient tissues and cancer cell lines. In patient samples, TNFRSF13B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF13B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
